Latest News and Press Releases

BASEL, Switzerland, Dec. 20, 2005 (PRIMEZONE) -- With new evidence of its potency against methicillin-resistant Staphylococcus aureus (MRSA) and broad spectrum of activity, ceftobiprole; in...

BASEL, Switzerland, Dec. 19, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it maintains global marketing and manufacturing rights to BAL8557 following Roche's...

BASEL, Switzerland, Oct. 11, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) today announced the start of an additional pivotal Phase III trial with its development partner Johnson &...

BASEL, Switzerland, Sept. 8, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. announced today positive results from its phase II clinical trial evaluating BAL8557, Basilea's broad-spectrum antifungal....

BASEL, Switzerland, Aug. 24, 2005 (PRIMEZONE) -- Basilea realizes CHF 95.9 million from Johnson & Johnson under ceftobiprole license agreement in the first half of 2005; cash and short-term...

BASEL, Switzerland, April 13, 2005 (PRIMEZONE) -- In his presentation to shareholders yesterday, Anthony Man, MD, Basilea's CEO, commented on the 2004 business year: "The focus of Basilea over the...

Basel, Switzerland, April 8, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today the start of its international phase III program for BAL5788, a novel broad spectrum, anti-methicillin...

BASEL, Switzerland, March 10, 2005 (PRIMEZONE) -- Basilea: Combined cash and short-term investments increased to CHF 203.2 million as of December 31, 2004 compared to CHF 75.5 million at year-end...

BASEL, Switzerland, March 8, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced the advancement of the novel topical antibiotic BAL19403 into preclinical testing. BAL19403 is the most advanced of...

BASEL, Switzerland, Feb. 3, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it has entered into an exclusive worldwide agreement with Cilag AG International, a Johnson & Johnson...